Last reviewed · How we verify
Placebo to omarigliptin
Omarigliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor that increases incretin hormone levels to stimulate insulin secretion and reduce glucagon in response to elevated blood glucose.
Omarigliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor that increases incretin hormone levels to stimulate insulin secretion and reduce glucagon in response to elevated blood glucose. Used for Type 2 diabetes mellitus.
At a glance
| Generic name | Placebo to omarigliptin |
|---|---|
| Sponsor | Merck Sharp & Dohme LLC |
| Drug class | DPP-4 inhibitor |
| Target | DPP-4 (dipeptidyl peptidase-4) |
| Modality | Small molecule |
| Therapeutic area | Diabetes |
| Phase | Phase 3 |
Mechanism of action
DPP-4 inhibitors work by blocking the enzyme that degrades glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), thereby prolonging their action. This leads to glucose-dependent insulin secretion and suppression of glucagon secretion, resulting in improved glycemic control in type 2 diabetes patients.
Approved indications
- Type 2 diabetes mellitus
Common side effects
- Hypoglycemia
- Nasopharyngitis
- Headache
- Upper respiratory tract infection
Key clinical trials
- Omarigliptin Add-on to Insulin in Japanese Participants With Type 2 Diabetes Mellitus (T2DM, MK-3102-039) (PHASE4)
- Omarigliptin (MK-3102) Clinical Trial - Placebo- and Sitagliptin-Controlled Monotherapy Study in Japanese Patients With Type 2 Diabetes Mellitus (MK-3102-020) (PHASE3)
- A Study to Assess Cardiovascular Outcomes Following Treatment With Omarigliptin (MK-3102) in Participants With Type 2 Diabetes Mellitus (MK-3102-018) (PHASE3)
- Addition of Omarigliptin (MK-3102) to Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Combination Therapy With Glimepiride and Metformin (MK-3102-022) (PHASE3)
- Study to Evaluate the Safety and Efficacy of the Addition of Omarigliptin (MK-3102) Compared With the Addition of Sitagliptin in Participants With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin (MK-3102-026) (PHASE3)
- A Study to Evaluate the Safety, Tolerability, and Efficacy of the Addition of Omarigliptin (MK-3102) to Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Metformin Therapy (MK-3102-024) (PHASE3)
- Omarigliptin (MK-3102) Clinical Trial - Add-on to Oral Antihyperglycemic Agent Study in Japanese Participants With Type 2 Diabetes Mellitus (MK-3102-015) (PHASE3)
- A Study to Assess the Safety and Efficacy of Omarigliptin (MK-3102) in Participants With Type 2 Diabetes Mellitus (T2DM) and Inadequate Glycemic Control (MK-3102-011) (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Placebo to omarigliptin CI brief — competitive landscape report
- Placebo to omarigliptin updates RSS · CI watch RSS
- Merck Sharp & Dohme LLC portfolio CI